Repurposing pemafibrate to treat liver disease associated with metabolic disorders

FHS
July 10, 2024
7:20 pm

The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people.

Chest wall irradiation does not impact 10-year survival in intermediate-risk breast cancer

Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they underwent chest wall irradiation (CWI) after mastectomy, according to

December 12, 2024

COVID-19 pandemic disrupted cancer diagnoses, raising alarms for future healthcare resilience

The COVID-19 pandemic led to a notable decline in new cancer diagnoses in Manitoba, Canada, particularly affecting breast, colon, and rectal cancers. The study highlights

September 7, 2023

AI uncovers potential cancer drivers hidden in ‘junk’ regions of DNA

Using artificial intelligence, Garvan Institute researchers have found potential cancer drivers hidden in so-called ‘junk’ regions of DNA, opening up possibilities for a new approach

July 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.